- Home
- ZCMD vs BOLD Comparison
ZCMD vs BOLD Comparison
Compare ZCMD & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZCMD
- BOLD
- Stock Information
- Founded
- ZCMD 2012
- BOLD 2018
- Country
- ZCMD China
- BOLD United States
- Employees
- ZCMD N/A
- BOLD N/A
- Industry
- ZCMD Other Consumer Services
- BOLD
- Sector
- ZCMD Real Estate
- BOLD
- Exchange
- ZCMD Nasdaq
- BOLD Nasdaq
- Market Cap
- ZCMD 28.5M
- BOLD 24.4M
- IPO Year
- ZCMD 2020
- BOLD 2024
- Fundamental
- Price
- ZCMD $1.13
- BOLD $1.14
- Analyst Decision
- ZCMD
- BOLD Buy
- Analyst Count
- ZCMD 0
- BOLD 3
- Target Price
- ZCMD N/A
- BOLD $4.00
- AVG Volume (30 Days)
- ZCMD 246.4K
- BOLD 278.2K
- Earning Date
- ZCMD 01-01-0001
- BOLD 08-11-2025
- Dividend Yield
- ZCMD N/A
- BOLD N/A
- EPS Growth
- ZCMD N/A
- BOLD N/A
- EPS
- ZCMD N/A
- BOLD N/A
- Revenue
- ZCMD $15,864,773.00
- BOLD N/A
- Revenue This Year
- ZCMD N/A
- BOLD N/A
- Revenue Next Year
- ZCMD N/A
- BOLD N/A
- P/E Ratio
- ZCMD N/A
- BOLD N/A
- Revenue Growth
- ZCMD N/A
- BOLD N/A
- 52 Week Low
- ZCMD $0.95
- BOLD $1.00
- 52 Week High
- ZCMD $2.97
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- ZCMD 46.37
- BOLD N/A
- Support Level
- ZCMD $1.10
- BOLD N/A
- Resistance Level
- ZCMD $1.24
- BOLD N/A
- Average True Range (ATR)
- ZCMD 0.08
- BOLD 0.00
- MACD
- ZCMD -0.01
- BOLD 0.00
- Stochastic Oscillator
- ZCMD 9.95
- BOLD 0.00
About ZCMD Zhongchao Inc.
ZHONGCHAO Inc is an offshore holding company incorporated in the Cayman Islands. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provide the healthcare information, education, and training services to the healthcare professionals under their MDMOOC brand. It also provide focused patient management services, through Zhongxun IT system and WeChat mini program and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.